Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Update

Aethlon Medical, Inc. (NASDAQ:AEMD) was the recipient of a large decrease in short interest in May. As of May 31st, there was short interest totalling 11,800 shares, a decrease of 86.3% from the May 15th total of 86,400 shares. Based on an average daily volume of 23,900 shares, the short-interest ratio is currently 0.5 days. Approximately 0.1% of the shares of the company are sold short.

Institutional Trading of Aethlon Medical

Hedge funds and other institutional investors have recently modified their holdings of the company. Virtu Financial LLC purchased a new position in shares of Aethlon Medical during the 4th quarter valued at $81,000. Boothbay Fund Management LLC purchased a new stake in Aethlon Medical in the 4th quarter worth $186,000. Sassicaia Capital Advisers LLC bought a new stake in Aethlon Medical during the fourth quarter valued at about $31,000. Allegiance Financial Group Advisory Services LLC bought a new stake in Aethlon Medical during the fourth quarter valued at about $26,000. Finally, Armistice Capital LLC purchased a new position in shares of Aethlon Medical in the first quarter valued at about $511,000. 1.99% of the stock is owned by hedge funds and other institutional investors.

Aethlon Medical Trading Down 2.5%

NASDAQ AEMD opened at $1.97 on Friday. Aethlon Medical has a 12 month low of $1.90 and a 12 month high of $8.44. The stock has a market cap of $3.96 million, a price-to-earnings ratio of -1.25 and a beta of 1.89. The company’s 50 day moving average is $2.92 and its two-hundred day moving average is $3.86.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on AEMD. Wall Street Zen began coverage on Aethlon Medical in a research report on Thursday, May 15th. They set a “sell” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $56.00 price objective on shares of Aethlon Medical in a research note on Monday, March 10th.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.